A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer

Overview

This is a phase III, multicenter, prospective, randomized, controlled clinical trial to evaluate the impact of omentectomy for advanced gastric cancer on patient survival.

Description

In order to evaluate the impact of omentectomy for advanced gastric cancer on patient survival, we designed this trial. Patients who received curative gastrectomy were divided into two groups based on whether they underwent omentectomy. The purpose of this study is to prove the non-inferiority of omentum preservation compared with omentectomy in patients with T3-T4a gastric cancer.

Eligibility

Inclusion Criteria:

1. Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16);
2. Physical condition and organ function allows to tolerable abdominal surgery;
3. Willing and able to comply with the program during the study period;
4. Written informed consent provided;
5. ≥ 18 and ≤ 70 years of age; preoperative gastric cancer patients with pathologically confirmed;
6. With more than a 6-month life expectancy;
7. No other serious concomitant diseases; Sufficient organ functions;
8. No previous history of chemotherapy or radiotherapy;
9. All patients accept 8 cycles XELOX chemotherapy regimen;
10. Clinical stage: T3-4aN0-+M0; 11 . Macroscopic types :Borrmann I-III;
11. Not greater curvature tumor; with distal or total gastrectomy； 13. No previous surgery for any abdominal disease, except an appendectomy for appendicitis, a laparoscopic cholecystectomy for gallbladder stones; No previous history of peritonitis, pancreatitis;
12. Karnofsky performance status (KPS)>60; Eastern Cooperative Oncology Group Performance Status (ECOG): 0-1.

Exclusion Criteria:

        Pregnancy or breast feeding; 2. Patients with Serious liver disease (such as cirrhosis,
        etc.), kidney disease, respiratory disease or uncontrolled diabetes, hypertension and other
        chronic systemic diseases, heart disease with Clinical symptoms, such as congestive heart
        failure, coronary heart disease symptoms, drug is difficult to control arrhythmia,
        hypertension, or six months had a myocardial infarction attack, or cardiac insufficiency;
        3. Organ transplantation patients need immunosuppressive therapy; 4. Severe recurrent
        infections were not controlled or with other serious concomitant diseases; 5. Patients got
        other primary malignant tumors (except curable skin basal cell carcinoma and cervical
        cancer in situ) except gastric cancer within 5 years; 6. Psychiatric disease which require
        treatment; 7. Have the history of organ transplantation; 8. Within 6 months before study
        starts and in the process of this study, patients participate in other clinical researches.
        9. Advanced gastric cancer with omentum invasion 10. Patients can't treated with XELOX
        after surgery; 11 . Macroscopic types : Borrmann IV; 12. Tumor invasion of adjacent organ
        (T4b) or with distant metastasis#M1 #; 13. Tumor invasion the greater curvature invasion.